“We have the knowledge, technology, plan, team and facilities to be the first to develop effective anti-aging therapeutics”
On October 27, 2022, Rapha Capital held a Ponce-Deliver Anti-Aging Investor Meeting at its R&D Headquarters at K2 Biolabs in Houston, Texas. The event gave us the opportunity to review the exciting and valuable work being done at Rapha Capital-companies Ponce Therapeutics and Deliver Therapeutics and introduce the current opportunities available to participate in these and other Rapha Capital-managed investments.
We look at the exciting programs currently in progress and what is to come in 2022 and beyond.
Jump to chapters using the playbar icons 
or view the list of all chapters using the chapters list icon located in the bottom right of the video.
Ponce-Deliver Anti-Aging Investor Meeting Agenda
Introduction - Kevin Slawin, MD
0:00:00 – 0:10:08
History, Biology, Mechanisms, & Market $ - David Spencer, PhD
Immunology
0:10:08 – 0:18:34
Aging
0:18:34 – 0:30:19
Rapha Capital Companies
Ponce Therapeutics – Overview of Anti-Aging Programshttps://poncetherapeutics.com - Click here to view website
0:30:19 – 0:55:15
Deliver Therapeutics - Introduction of the “Targetome https://delivertherapeutics.com - Click here to view website
0:55:15 – 1:00:52
Proof-of-concept of DELiver DECL technology in identifying a universal Tyrosine Kinase Inhibitor (TKI)
1:00:52 – 1:18:41
Combination of DEL with All-Hydrocarbon Stapled peptides (AHSPs) to target Protein-Protein Interactions (PPIs) that can disrupt the fundamental biologic mechanisms of aging
1:18:41 – 1:32:17
Anti-Aging Pipeline
1:32:17 – 1:34:46
Key Takeaways - Kevin Slawin, MD
1:40:15 – 1:51:21
Investment Vehicle & Terms
1:51:21 – 2:09:14
Key Takeaways
-
Based on the trajectory of development of Oncologic ImmunoTherapeutics, we should be on the cusp of developing effective therapeutics that can arrest or reverse aging
-
Our leadership was at the forefront of Oncologic ImmunoTherapeutic development with their first successful company, Bellicum Pharmaceuticals Inc.
- Reached a near $1 billion valuation in 2014
- We have learned valuable lessons during that experience that we have now applied with Ponce and Deliver Therapeutics
-
We have the knowledge, technology, plan, team and facilities to be the first to develop effective anti-aging therapeutics
- Ponce – lead product targeting skin
- Gene therapy to rejuvenate skin by eliminating senescent cells using our proprietary senescent cell-gene targeting technologies and proprietary ApoptiCIDeTM cell elimination technology
- Deliver – drug discovery platform technologies
- Pan TKI inhibitor – 5 drug candidates out of 7 billion in multibillion $ market
- All Hydrocarbon Stapled Peptide to inhibit Fox04-p53 pro-senescent pathway for systemic administration and reversal of aging
-
We have already created great value and made significant progress towards these goals
We are evaluating two potential delivery technologies for our lead product, ReBeautTM targeting the elimination of senescent cells in the skin:
Due to its unique design the MicronJetTM– microneedle is one of the shallowest and most consistent forms of intradermal delivery. The easy-to-use MicronJetTM provides one of most shallow and consistent forms of intradermal delivery. Its minute size (0.6mm) allows for shallow injection. Being barely visible to the naked eye makes it also significantly less painful than regular injections, as well as much less intimidating. It requires a short learning curve, enabling practitioners to quickly learn how to use the device.
- Blebs of >6 mm were observed 99% of the time, evaluated in over 1,000 injections on more than 800 subjects
- Significantly less painful and intimidating than a regular needle and syringe, with the potential for improved compliance
- Smallest hollow needle in the market allows for a practically painless injection
